

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2017 December 15; 9(12): 457-501



**MINIREVIEWS**

- 457 Neoadjuvant therapy for resectable pancreatic cancer

*Rahman SH, Urquhart R, Molinari M*

**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 466 Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study

*Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, van Diest PJ*

**META-ANALYSIS**

- 475 Laparoscopic vs open complete mesocolic excision with central vascular ligation for colon cancer: A systematic review and meta-analysis

*Negoi I, Hostiuc S, Negoi RI, Beuran M*

**CASE REPORT**

- 492 Cystic metastasis from a mucinous adenocarcinoma of duodenum mimicking type II choledochal cyst: A case report

*Kim YN, Song JS*

- 497 Extrapaneatic solid pseudopapillary neoplasm followed by multiple metastases: Case report

*Wu H, Huang YF, Liu XH, Xu MH*

## Contents

*World Journal of Gastrointestinal Oncology*  
Volume 9 Number 12 December 15, 2017

### ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Wei-Hao Sun, PhD, Professor, Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

### AIM AND SCOPE

*World Journal of Gastrointestinal Oncology* (*World J Gastrointest Oncol*, *WJGO*, online ISSN 1948-5204, DOI: 10.4251) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJGO* covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

### INDEXING/ABSTRACTING

*World Journal of Gastrointestinal Oncology* is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, and PubMed Central.

### FLYLEAF

#### I-IV Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Ya-Jing Lu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*  
Proofing Editorial Office Director: *Xin-Xia Song*

NAME OF JOURNAL  
*World Journal of Gastrointestinal Oncology*

ISSN  
ISSN 1948-5204 (online)

LAUNCH DATE  
February 15, 2009

FREQUENCY  
Monthly

EDITORS-IN-CHIEF  
**Hsin-Chen Lee, PhD, Professor**, Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan

**Dimitrios H Roukos, MD, PhD, Professor**, Personalized Cancer Genomic Medicine, Human Cancer Biobank Center, Ioannina University, Metabatiko Ktirio Panepistimiou Ioanninon, Office 229, Ioannina, TK 45110, Greece

EDITORIAL BOARD MEMBERS  
All editorial board members resources online at <http://www.wjgnet.com>

[www.wjgnet.com/1948-5204/editorialboard.htm](http://www.wjgnet.com/1948-5204/editorialboard.htm)

EDITORIAL OFFICE  
Xiu-Xia Song, Director  
*World Journal of Gastrointestinal Oncology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLISHER  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive,  
Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

PUBLICATION DATE  
December 15, 2017

COPYRIGHT  
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT  
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS  
<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION  
<http://www.f6publishing.com>

## Extrapancreatic solid pseudopapillary neoplasm followed by multiple metastases: Case report

Hao Wu, Yan-Fen Huang, Xiang-Hong Liu, Mei-Hua Xu

Hao Wu, Yan-Fen Huang, Xiang-Hong Liu, Mei-Hua Xu, Department of Gastroenterology, Xiangya Hospital of Central South University, Changsha 410008, Hunan Province, China

ORCID number: Hao Wu (0000-0002-8270-1307); Yan-Fen Huang (0000-0002-4496-830x); Xiang-Hong Liu (0000-0002-2140-9409); Mei-Hua Xu (0000-0003-3560-2645).

**Author contributions:** All authors contributed to the acquisition of data, writing, and revision of this manuscript.

**Informed consent statement:** Patients were not required to give informed consent to the study because the participant is deceased.

**Conflict-of-interest statement:** We have no pertinent financial relationships to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Dr. Mei-Hua Xu, MD, PhD, Professor, Department of Gastroenterology, Xiangya Hospital of Central South University, No 87 Xiangya Road, Changsha 410008, Hunan Province, China. [w339812016@csu.edu.cn](mailto:w339812016@csu.edu.cn)  
Telephone: +86-731-89753923

Received: June 24, 2017

Peer-review started: June 26, 2017

First decision: August 7, 2017

Revised: August 24, 2017

Accepted: November 3, 2017

Article in press: November 3, 2017

Published online: December 15, 2017

### Abstract

Solid pseudopapillary neoplasm (SPN), also known as Gruber-Frantz tumor, is a rare form of neoplasm that almost exclusively occurs in the pancreas and in young females. While the potential of malignancy is low for SPN, these tumors can mimic other diseases and require a meticulous investigation and a standard treatment by total surgical resection. We present an unusual case of SPN arising in the mesentery of a 40-year-old man with subsequent multiple metastases. Histopathological examination showed similar properties of the mesenteric neoplasm to those of SPN in pancreas. Although the mass was surgically removed, the patient died of recurrent disease 4 years after the initial presentation. We speculate that SPN originates from pancreatic progenitor cells. Further histopathological analyses are required for the prediction of SPN recurrence after resection.

**Key words:** Solid pseudopapillary neoplasm; Mesentery; Metastasis

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Solid pseudopapillary neoplasm (SPN) has been recognized by World Health Organization since 2010, and classified as a low malignant potential neoplasm. Such neoplasm is characterized by the presence of a mutation in the gene that encodes  $\beta$ -catenin.  $\beta$ -catenin is an important factor in the Wnt signaling pathway ( $\beta$ -catenin-dependent Wnt signaling). The identification of extrapancreatic SPN, especially in the mesentery, indicates a possible endoderm link between pancreatic progenitor cells and SPN cells.

Wu H, Huang YF, Liu XH, Xu MH. Extrapancreatic solid pseudopapillary neoplasm followed by multiple metastases: Case




report. *World J Gastrointest Oncol* 2017; 9(12): 497-501 Available from: URL: <http://www.wjgnet.com/1948-5204/full/v9/i12/497.htm> DOI: <http://dx.doi.org/10.4251/wjgo.v9.i12.497>

## INTRODUCTION

Solid pseudopapillary neoplasm (SPN) is a rare and indolent type of neoplasm that occurs in pancreas; SPN forms 0.3% to 2.7% of all pancreatic exocrine tumors. A large body of SPN indices are found in young female patients, and well-circumscribed. A margin negative surgical resection shows curative result in majority of cases<sup>[1-3]</sup>; recurrence after surgical resection is reported in 2% to 10% of patients<sup>[4,5]</sup>. Patients with unresectable SPN may have a long-term survival (5 years), and require complex chemo- and radio-therapy treatments; the efficacy of adjuvant therapies in the SPN treatment remains largely unknown and a clinical challenge. Thus, it is important to differentiate the risk of recurrence in SPN patients. An extrapancreatic development of SPN is a rare incident; only 16 cases of extrapancreatic SPN have been reported so far worldwide (Table 1). In the present article, we report a patient, in whom SPN was found in the mesentery; no invasion or attachments to adjacent organs was observed. To the best of our knowledge, this article is the first to report a SPN case in the mesentery.

## CASE REPORT

A 40-year-old Chinese male came to hospital on November 15, 2012. His main complaint was abdominal distention that lasted over 6 mo. His physical examination revealed a 30 cm soft mass in the abdomen. An abdominal computed tomography (CT) scan exhibited solid and mixed cystic lesions, measuring > 28 cm diameter (Figure 1). Patient's blood test results were unremarkable. On November 22, 2012, the patient underwent an exploratory laparotomy, and the tumor protruding from the mesentery was completely excised. At that time, no invasion or attachments to adjacent organs was observed. In addition, the postoperative course was uneventful. The resected specimen of the mesenteric tumor was 25 cm × 15 cm × 28 cm, and showed a multilobulated structure with rich microvasculature. Microscopic characterization of the tumor showed that the tumor formation was a mix of solid and pseudopapillary areas. There was no evidence of pancreatic tissue in the analyzed sample. Further, the specimen was positive for alpha-1-antitrypsin, vimentin, CD56 and  $\beta$ -catenin immunostaining, whereas negative for S-100, neuron-specific enolase, E-cadherin, calretinin, progesterone receptor, chromogranin, and pancytokeration (Figure 2). Such results led to the diagnosis of SPN in the mesentery. Following 3.5 years, the patient continued to complain about abdominal distention and occasional polypnea. An abdominal CT scan exhibited multiple tumors in peritoneum, greater omentum, and colonic wall (Figure 3). Meanwhile, cells in the pleural effusion were



**Figure 1** An abdominal computed tomography scan exhibited solid and mixed cystic lesions, measuring > 28 cm diameter (black arrow). The tumor was apart from the pancreas (white arrow).

found positive for alpha-1-antitrypsin, vimentin, CD56 and  $\beta$ -catenin. It was clear that the patient was suffering from recurrence of the disease. Before the surgical operation to clean the recurrent tumors, the patient received the treatment of 60 mg cisplatin by hyperthermic intraperitoneal chemotherapy (HIPEC). Unfortunately, there was no response to the treatment, and the patient was transferred to the palliative care unit. Soon after the patient's physical conditions worsened, we lost the patient on November 2016, 4 years after the initial surgery.


## DISCUSSION

SPN has been recognized by the WHO classification as a low malignant potential neoplasm in 2010<sup>[3]</sup>. It was first named as Gruber-Frantz tumor and after that it had been called the pancreatic solid papillary epithelial neoplasm, pancreatic papillary cystic neoplasm, pancreatic solid cystic tumor and solid pseudopapillary tumor. The differential diagnosis of SPN may include: pseudocyst, pancreatic mucinous neoplasms, well-differentiated ductal adenocarcinoma, pancreatic endocrine neoplasm, and acinic cell carcinoma. The pathogenesis of SPN remains unclear. Likewise, genetic events that contribute to the development of SPN are yet to be discovered. There are two basic proposals for the SPN origin: (1) genital ridge-related cells and (2) pancreatic progenitor cells<sup>[1,6]</sup>. To note, an important proportion of SPN cases show mutations in the somatic  $\beta$ -catenin coding gene (*CTNNB1*)<sup>[7-9]</sup>. Such mutations can affect Wnt signaling pathways as well as self-renewal capability of stem cells<sup>[10]</sup>. SPN cells were reported to be positive for  $\beta$ -catenin, vimentin, alpha-1-anti-trypsin, CD10, CD56, and progesterone receptors by immunohistochemical analysis<sup>[11]</sup>; however this staining pattern fails to reveal a clear phenotypic relationship between SPN and any of the defined cell lineages of the pancreas. Thereby, it can be speculated as SPN cells show multipotential differentiation. According to the study concerned with the embryonic development of the human pancreas, dorsal and ventral pancreatic buds were reported to proliferate

**Table 1** Review of extra-pancreatic solid pseudopapillary neoplasm


Ref.	Age	Sex	Location	Size (cm)	Procedure	Follow-up
Miyazaki <i>et al</i> <sup>[19]</sup>	22	F	Retroperitoneum	7	Laparoscopy	6 mo NED
Hibi <i>et al</i> <sup>[20]</sup>	45	M	Omentum	15	Laparoscopy	96 mo DOD
Deshpande <i>et al</i> <sup>[21]</sup>	17	F	Left ovary	25.5	Open surgery	72 mo NED
	57	F	Right ovary	3	Open surgery	NA
	21	F	Left ovary	14	Open surgery	NA
He <i>et al</i> <sup>[22]</sup>	39	F	Right ovary	6	Laparoscopy	36 mo NED
Fukunaga <i>et al</i> <sup>[23]</sup>	46	F	Omentum	5	Laparoscopy	3 mo NED
Ishikawa <i>et al</i> <sup>[24]</sup>	13	F	Mesocolon	4	Open surgery	36 mo NED
Guo <i>et al</i> <sup>[25]</sup>	47	F	Retroperitoneum	16	Open surgery	14 mo NED
Geng <i>et al</i> <sup>[26]</sup>	37	F	Retroperitoneum	8	Open surgery	NA
Zhu <i>et al</i> <sup>[27]</sup>	22	F	Retroperitoneum	6	Laparoscopy	14 mo NED
Chen <i>et al</i> <sup>[28]</sup>	47	F	Left ovary	6	Open surgery	18 mo NED
Cheuk <i>et al</i> <sup>[29]</sup>	25	F	Right ovary	16.5	Open surgery	144 mo NED
Walter <i>et al</i> <sup>[30]</sup>	32	F	Stomach	10	Open surgery	24 mo LWD
	73	M	Duodenum	14	Open surgery	3 mo DOD
Stoll <i>et al</i> <sup>[31]</sup>	48	F	Left ovary	8	Open surgery	9 mo NED
Present case	40	M	Mesentery	28	Open surgery	48 mo DOD

NED: No evidence of disease; DOD: Dead of disease; LWD: Live with disease; NA: Not available; F: Female; M: Male.



**Figure 2** Histological and immunohistochemical findings of the tumor ( $\times 200$ ). The tumor cells are arranged in solid sheets, pseudopapillary and microcysts (A and B: Hematoxylin-eosin stain), and are immunohistochemically positive for alpha-1-antitrypsin (C),  $\beta$ -catenin (D: Cytoplasmic and nuclear staining), CD56 (E), whereas negative for chromogranin (F).





**Figure 3** An abdominal computed tomography scan exhibited multiple tumors in peritoneum, greater omentum, and colonic wall (white arrow).

from gut epithelium of endoderm during the 4<sup>th</sup> week of gestation. Dorsal pancreas fuses with ventral pancreas at the 7<sup>th</sup> week of gestation due to the rotation of the stomach and duodenum development<sup>[12]</sup>. Identification of extrapancreatic SPN in the ovary, retroperitoneum and the omentum, as listed in Table 1, indicates a possible endoderm link, substantiated by the migration of pancreas during embryogenesis. We therefore believe that extrapancreatic SPN originates from pancreatic progenitor cells.

In SPN patients, tumor resection confers an 8 year survival rate in 85% of cases; nevertheless, local recurrence or distant metastases can occur in some patients<sup>[13]</sup>. Histological and clinical parameters for prediction of disease recurrence after the initial surgical operation remain a challenge as there is still no consensus in the medical community. Many clinicians and researchers have been working to determine such criteria. For example, Kang *et al.*<sup>[14]</sup> listed: (1) a tumor size larger than 8 cm; (2) cellular atypia; (3) vascular invasion; (4) perineural invasion; (5) systemic metastasis; and (6) peritoneal seeding as significant prognostic factors for tumor recurrence in a multicenter study. A case series study conducted by Yang *et al.*<sup>[15]</sup> showed that vascular invasion, extra-pancreatic invasion, lymph node metastasis, and Ki-67 index  $\geq 4\%$  are associated with SPN recurrence. It is important to note that a rupture of the tumor or laparoscopic biopsy may seed the tumor cells into the peritoneal cavity, and could be an etiological factor responsible for the peritoneal recurrence<sup>[16]</sup>. Nonetheless, a recurrence prediction scoring model require more investigation. Such model will help clinicians to distinguish a high-risk group from low-risk group. Likewise, there is still no consensus on the treatment strategy in patients with SPN recurrence. A previous report described a 35 years old woman relapsing 8 mo after the resection of an SPN, which ruptured preoperatively. The patient firstly underwent a complete cytoreductive surgery, but relapsed within 8 mo, and received another cytoreductive surgery combined with HIPEC (oxaliplatin and irinotecan). At 31 mo of follow-up, the patient showed no evidence of disease recurrence<sup>[17]</sup>.

Thus, a complete cytoreductive surgery combined with HIPEC stands as an important treatment solution for high-risk group of SPN. Further, another report concluded that SPN are radiosensitive, and can be successfully treated by using radiation therapy<sup>[18]</sup>. Future clinical and molecular studies are required to provide more precise tools to predict the biological behavior of SPN.

## ARTICLE HIGHLIGHTS

### Case characteristics

Abdominal distension.

### Clinical diagnosis

Abdominal mass.

### Differential diagnosis

Pancreatic mucinous neoplasms.

### Laboratory diagnosis

All labs were within normal limits.

### Imaging diagnosis

Mesenchymal neoplasm.

### Pathological diagnosis

Solid pseudopapillary neoplasm (SPN).

### Treatment

Complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.

### Related reports

Grading and staging play an important role in treatment and prognosis.

### Term explanation

SPN: Solid pseudopapillary neoplasm.

### Experiences and lessons

Future clinical and molecular studies are required to provide more precise tools to predict the biological behavior of SPN.

## REFERENCES

- 1 Mao C, Guvendi M, Domenico DR, Kim K, Thomford NR, Howard JM. Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. *Surgery* 1995; **118**: 821-828 [PMID: 7482268 DOI: 10.1016/s0039-6060(05)80271-5]
- 2 Yu PF, Hu ZH, Wang XB, Guo JM, Cheng XD, Zhang YL, Xu Q. Solid pseudopapillary tumor of the pancreas: a review of 553 cases in Chinese literature. *World J Gastroenterol* 2010; **16**: 1209-1214 [PMID: 20222163 DOI: 10.3748/wjg.v16.i10.1209]
- 3 Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumors of the Digestive System. 4th edn. Lyon: International Agency for Research on Cancer, 2010
- 4 Lubezky N, Papoulas M, Lessing Y, Gitstein G, Brazowski E, Nachmany I, Lahat G, Goykhman Y, Ben-Yehuda A, Nakache R, Klausner JM. Solid pseudopapillary neoplasm of the pancreas: Management and long-term outcome. *Eur J Surg Oncol* 2017; **43**: 1056-1060 [PMID: 28238521 DOI: 10.1016/j.ejso.2017.02.001]

- 5 **Marchegiani G**, Andrianello S, Massignani M, Malleo G, Maggino L, Paiella S, Ferrone CR, Luchini C, Scarpa A, Capelli P, Mino-Kenudson M, Lillemoe KD, Bassi C, Castillo CF, Salvia R. Solid pseudopapillary tumors of the pancreas: Specific pathological features predict the likelihood of postoperative recurrence. *J Surg Oncol* 2016; **114**: 597-601 [PMID: 27471041 DOI: 10.1002/jso.24380]
- 6 **Kosmahl M**, Seada LS, Jänig U, Harms D, Klöppel G. Solid-pseudopapillary tumor of the pancreas: its origin revisited. *Virchows Arch* 2000; **436**: 473-480 [PMID: 10881741 DOI: 10.1007/s004280050475]
- 7 **Springer S**, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbys L, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioaka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology* 2015; **149**: 1501-1510 [PMID: 26253305 DOI: 10.1053/j.gastro.2015.07.041]
- 8 **Guo M**, Luo G, Jin K, Long J, Cheng H, Lu Y, Wang Z, Yang C, Xu J, Ni Q, Yu X, Liu C. Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. *Int J Mol Sci* 2017; **18**: pii: E81 [PMID: 28054945 DOI: 10.3390/ijms18010081]
- 9 **Abraham SC**, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, Cameron JL, Wu TT, Hruban RH. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. *Am J Pathol* 2002; **160**: 1361-1369 [PMID: 11943721 DOI: 10.1016/s0002-9440(10)62563-1]
- 10 **Clevers H**. Wnt/beta-catenin signaling in development and disease. *Cell* 2006; **127**: 469-480 [PMID: 17081971 DOI: 10.1016/j.cell.2006.10.018]
- 11 **Haq S**, Dietz R, Perez MC. Recognizing the distinct cytomorphologic features of solid pseudopapillary neoplasm of the pancreas. *J Gastrointest Oncol* 2016; **7**: E13-E16 [PMID: 27034801 DOI: 10.3978/j.issn.2078-6891.2015.121]
- 12 **O'Rahilly R**. The timing and sequence of events in the development of the human digestive system and associated structures during the embryonic period proper. *Anat Embryol (Berl)* 1978; **153**: 123-136 [PMID: 677467 DOI: 10.1007/bf00343369]
- 13 **Jutric Z**, Rozenfeld Y, Grendar J, Hammill CW, Cassera MA, Newell PH, Hansen PD, Wolf RF. Analysis of 340 Patients with Solid Pseudopapillary Tumors of the Pancreas: A Closer Look at Patients with Metastatic Disease. *Ann Surg Oncol* 2017; **24**: 2015-2022 [PMID: 28299507 DOI: 10.1245/s10434-017-5772-z]
- 14 **Kang CM**, Choi SH, Kim SC, Lee WJ, Choi DW, Kim SW; Korean Pancreatic Surgery Club. Predicting recurrence of pancreatic solid pseudopapillary tumors after surgical resection: a multicenter analysis in Korea. *Ann Surg* 2014; **260**: 348-355 [PMID: 24743622 DOI: 10.1097/SLA.0000000000000583]
- 15 **Yang F**, Yu X, Bao Y, Du Z, Jin C, Fu D. Prognostic value of Ki-67 in solid pseudopapillary tumor of the pancreas: Huashan experience and systematic review of the literature. *Surgery* 2016; **159**: 1023-1031 [PMID: 26619927 DOI: 10.1016/j.surg.2015.10.018]
- 16 **Tajima Y**, Kohara N, Maeda J, Inoue K, Kitasato A, Natsuda K, Irie J, Adachi T, Kuroki T, Eguchi S, Kanematsu T. Peritoneal and nodal recurrence 7 years after the excision of a ruptured solid pseudopapillary neoplasm of the pancreas: report of a case. *Surg Today* 2012; **42**: 776-780 [PMID: 22706721 DOI: 10.1007/s00595-012-0208-7]
- 17 **Honore C**, Goere D, Dartigues P, Burtin P, Dumont F, Elias D. Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz's tumour) of the pancreas treated with HIPEC. *Anticancer Res* 2012; **32**: 1069-1073 [PMID: 22399634]
- 18 **Fried P**, Cooper J, Balthazar E, Fazzini E, Newall J. A role for radiotherapy in the treatment of solid and papillary neoplasms of the pancreas. *Cancer* 1985; **56**: 2783-2785 [PMID: 4052952 DOI: 10.1002/1097-0142(19851215)56:123.0.co;2-q]
- 19 **Miyazaki Y**, Miyajima A, Maeda T, Yuge K, Hasegawa M, Kosaka T, Kikuchi E, Kameyama K, Jinzaki M, Nakagawa K, Oya M. Extrapaneatic solid pseudopapillary tumor: case report and review of the literature. *Int J Clin Oncol* 2012; **17**: 165-168 [PMID: 21656203 DOI: 10.1007/s10147-011-0261-z]
- 20 **Hibi T**, Ojima H, Sakamoto Y, Kosuge T, Shimada K, Sano T, Sakamoto M, Kitajima M, Yamasaki S. A solid pseudopapillary tumor arising from the greater omentum followed by multiple metastases with increasing malignant potential. *J Gastroenterol* 2006; **41**: 276-281 [PMID: 16699862 DOI: 10.1007/s00535-005-1753-2]
- 21 **Deshpande V**, Oliva E, Young RH. Solid pseudopapillary neoplasm of the ovary: a report of 3 primary ovarian tumors resembling those of the pancreas. *Am J Surg Pathol* 2010; **34**: 1514-1520 [PMID: 20871224 DOI: 10.1097/PAS.0b013e3181f133e9]
- 22 **He S**, Yang X, Zhou P, Cheng Y, Sun Q. Solid pseudopapillary tumor: an invasive case report of primary ovarian origin and review of the literature. *Int J Clin Exp Pathol* 2015; **8**: 8645-8649 [PMID: 26339451]
- 23 **Fukunaga M**. Pseudopapillary solid cystic tumor arising from an extrapancreatic site. *Arch Pathol Lab Med* 2001; **125**: 1368-1371 [PMID: 11570919 DOI: 10.1043/0003-9985(2001)125:0.CO;2]
- 24 **Ishikawa O**, Ishiguro S, Ohhigashi H, Sasaki Y, Yasuda T, Imaoka S, Iwanaga T, Nakaizumi A, Fujita M, Wada A. Solid and papillary neoplasm arising from an ectopic pancreas in the mesocolon. *Am J Gastroenterol* 1990; **85**: 597-601 [PMID: 2337064]
- 25 **Guo X**, Li N, Ren K, Wu L, Ma LI, Wu S, Xie F, Feng Z. Extrapaneatic solid pseudopapillary tumors: A clinicopathological analysis of two cases. *Mol Clin Oncol* 2016; **4**: 845-850 [PMID: 27123293 DOI: 10.3892/mco.2016.802]
- 26 **Junzu G**, Yanbin S, Suxia W, Janjun D. A case of extrapancreatic solid pseudopapillary tumor in the retroperitoneum. *Jpn J Radiol* 2012; **30**: 598-601 [PMID: 22528341 DOI: 10.1007/s11604-012-0084-5]
- 27 **Zhu H**, Xia D, Wang B, Meng H. Extrapaneatic solid pseudopapillary neoplasm: Report of a case of primary retroperitoneal origin and review of the literature. *Oncol Lett* 2013; **5**: 1501-1504 [PMID: 23760027 DOI: 10.3892/ol.2013.1242]
- 28 **Chen Q**, Lu W, Lv W. Overlap of microcystic stromal tumor and primary solid pseudopapillary neoplasm of the ovary. *Int J Clin Exp Pathol* 2015; **8**: 11792-11797 [PMID: 26617928]
- 29 **Cheuk W**, Beavon I, Chui DT, Chan JK. Extrapaneatic solid pseudopapillary neoplasm: report of a case of primary ovarian origin and review of the literature. *Int J Gynecol Pathol* 2011; **30**: 539-543 [PMID: 21979589 DOI: 10.1097/PGP.0b013e31821724fb]
- 30 **Walter T**, Hommell-Fontaine J, Hervieu V, Adham M, Poncet G, Dumortier J, Lombard-Bohas C, Scoazec JY. Primary malignant solid pseudopapillary tumors of the gastroduodenal area. *Clin Res Hepatol Gastroenterol* 2011; **35**: 227-233 [PMID: 21345760 DOI: 10.1016/j.clinre.2011.01.004]
- 31 **Stoll LM**, Parvataneni R, Johnson MW, Gui D, Dorigo O, Sullivan P. Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm. *Hum Pathol* 2012; **43**: 1339-1343 [PMID: 22534259 DOI: 10.1016/j.humpath.2011.12.018]

**P-Reviewer:** Ikura Y, Lin J, Ramia JM, Şendur MAN **S-Editor:** Ji FF  
**L-Editor:** A **E-Editor:** Lu YJ







Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

